Bradley Pharmaceuticals Launches Kerol(TM) Topical Suspension and ROSULA(R) Clarifying Wash(TM)
28 Juin 2007 - 2:45PM
PR Newswire (US)
FAIRFIELD, N.J., June 28 /PRNewswire-FirstCall/ -- Bradley
Pharmaceuticals, Inc. (NYSE:BDY) today announced that its Doak
Dermatologics subsidiary recently launched two new product line
extensions from its Kerol(TM) and ROSULA(R) brand portfolios.
Kerol(TM) Topical Suspension (50% Urea), a potent keratolytic in a
vehicle containing lactic acid & salicylic acid, is an addition
to the line of Kerol(TM) Redi-Cloths keratolytic moisturizers.
Kerol(TM) Topical Suspension is indicated for the treatment of
hyperkeratotic conditions such as dry, rough skin, dermatitis,
psoriasis, xerosis, ichthyosis, eczema, keratosis pilaris,
keratosis palmaris, keratoderma, corns and calluses. ROSULA(R)
Clarifying Wash(TM) (sodium sulfacetamide 10% and sulfur 4%) is the
fourth product launched under the ROSULA(R) brand. The new
ROSULA(R) Clarifying Wash(TM) formulation combines 10% sodium
sulfacetamide and 4% sulfur in a urea vehicle and is indicated for
the treatment of acne vulgaris, acne rosacea and seborrrheic
dermatitis. Bradley launched the ROSULA(R) brand in 2003 with
ROSULA(R) Aqueous Gel which was followed by ROSULA(R) Aqueous
Cleanser and ROSULA(R) NS Medicated Pads. "Our Kerol(TM) and
ROSULA(R) brands have been well received by physicians and patients
and we anticipate that these new therapies will likewise be well
received," stated Daniel Glassman, President and CEO of Bradley
Pharmaceuticals. "One important part of our business strategy is to
develop brands through life cycle management that add value to the
medical community and patient care, and we believe that Kerol(TM)
Topical Suspension and ROSULA(R) Clarifying Wash(TM) both will meet
this objective." Important Product Safety Information About
Kerol(TM) Topical Suspension: KEROL(TM) Topical Suspension is for
external use only. Avoid contact with eyes, lips or mucous
membranes. If redness or irritation occurs, discontinue use.
Important Product Safety Information About ROSULA(R) Clarifying
Wash(TM): ROSULA(R) Clarifying Wash(TM) is contraindicated in
persons with known or suspected hypersensitivity to sulfonamides or
sulfur. ROSULA(R) Clarifying Wash(TM) is not to be used by patients
with kidney disease. Although rare, topical sodium sulfacetamide
may cause local irritation. For additional important information
about Kerol(TM) Topical Suspension or ROSULA(R) Clarifying Wash(TM)
please view full prescribing information at
http://www.bradpharm.com/ or request full prescribing information
by contacting Bradley Pharmaceuticals at 973-882-1505. Please visit
Bradley Pharmaceuticals web site at: http://www.bradpharm.com/.
About Bradley Pharmaceuticals, Inc. Bradley Pharmaceuticals, Inc.
was founded in 1985 as a specialty pharmaceutical company and
markets to niche physician specialties in the U.S. and
international markets. Bradley's success is based upon its core
strengths in marketing and sales, which enable the company to
Commercialize brands that fill unmet patient and physician needs;
Develop new products through life cycle management; and In-License
phase II and phase III drugs with long-term intellectual property
protection that upon approval leverage Bradley's marketing and
sales expertise to increase shareholder value. Bradley
Pharmaceuticals is comprised of Doak Dermatologics, specializing in
therapies for dermatology and podiatry; Kenwood Therapeutics,
providing gastroenterology, OB/GYN, respiratory and other internal
medicine brands; and A. Aarons, which markets authorized generic
versions of Doak and Kenwood therapies. Safe Harbor for
Forward-Looking Statements: This release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include statements
that address activities, events or developments that Bradley
expects, believes or anticipates will or may occur in the future,
such as Bradley's plans to in-license, develop and launch new and
enhanced products with long-term intellectual property protection
or other significant barriers to market entry, sales and earnings
estimates, other predictions of financial performance, timing of
payments on indebtedness, launches by Bradley of new products,
market acceptance of Bradley's products, and the achievement of
initiatives to enhance corporate governance and long-term
shareholder value. Forward-looking statements are based on
Bradley's experience and perception of current conditions, trends,
expected future developments and other factors it believes are
appropriate under the circumstances and are subject to numerous
risks and uncertainties, many of which are beyond Bradley's
control. These risks and uncertainties include Bradley's ability
to: launch VEREGEN(TM) at the end of 2007; predict the safety and
efficacy of ELESTRIN(TM) and VEREGEN(TM) in a commercial setting;
estimate sales; maintain adequate inventory levels; implement the
returns and inventory optimization plan timely, if at all; reduce
product returns; comply with the restrictive covenants under its
credit facility; refinance its credit facility; access the capital
markets on attractive terms or at all; favorably resolve the
pending SEC informal inquiry; maintain or increase sales of its
products; or effectively react to other risks and uncertainties
described from time to time in Bradley's SEC filings, such as
fluctuation of quarterly financial results, estimation of product
returns, chargebacks, rebates and allowances, concentration of
customers, reliance on third party manufacturers and suppliers,
litigation or other proceedings (including the pending class action
and shareholder derivative lawsuits), government regulation and
stock price volatility. Further, Bradley cannot accurately predict
the impact on its business of the approval, introduction, or
expansion by competitors of generic or therapeutically equivalent
or comparable versions of Bradley's products or of any other
competing products. In addition, actual results may differ
materially from those projected. Bradley undertakes no obligation
to publicly update any forward-looking statement, whether as a
result of new information, future events or otherwise. DATASOURCE:
Bradley Pharmaceuticals, Inc. CONTACT: Cecelia C. Heer of Bradley
Pharmaceuticals, Inc., +1-973-882-1505 ext. 252, Web site:
http://www.bradpharm.com/
Copyright
Bradley (NYSE:BDY)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Bradley (NYSE:BDY)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024